Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
2.77 0.03  (1.09%)
TradingVolume：465.55
07-23
2024
DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE
Publisher：
07-04
2024
MIMEIXIN (OXYCODONE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS) APPROVED FOR MARKETING IN CHINA
Publisher：
07-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Publisher：
06-27
2024
THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS PASSED PAI BY U.S. FDA WITH NO FDA-483 (78KB)
Publisher：
06-20
2024
JINYOUPING (ROTIGOTINE MICROSPHERES FOR INJECTION) APPROVED FOR MARKETING IN CHINA
Publisher：
06-06
2024
MEIBIRUI (PALIPERIDONE PALMITATE INJECTION) APPROVED FOR MARKETING IN CHINA
Publisher：
06-06
2024
NDA FILED FOR RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH IN JAPAN
Publisher：
06-04
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
Publisher：
05-28
2024
Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Publisher：
05-28
2024
Altered Memorandum of Association and Bye-laws
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume：465.55
2.77
0.03  (1.09%)
Announcement & Circular
07-23
2024
DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE
07-04
2024
MIMEIXIN (OXYCODONE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS) APPROVED FOR MARKETING IN CHINA
07-02
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
06-27
2024
THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS PASSED PAI BY U.S. FDA WITH NO FDA-483 (78KB)
06-20
2024
JINYOUPING (ROTIGOTINE MICROSPHERES FOR INJECTION) APPROVED FOR MARKETING IN CHINA
06-06
2024
MEIBIRUI (PALIPERIDONE PALMITATE INJECTION) APPROVED FOR MARKETING IN CHINA
06-06
2024
NDA FILED FOR RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH IN JAPAN
06-04
2024
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
05-28
2024
Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
05-28
2024
Altered Memorandum of Association and Bye-laws
First
1
2
3
4
5
Last